Chiesi Global Rare Diseases has rapidly evolved from a small, regional rare‑disease business into a global organization, leveraging strategic deals and development bets to reshape standards of care for patients worldwide. Giacomo Chiesi, head of the unit, discusses how the business has grown through acquisitions, its move into CRISPR gene editing and blood–brain barrier‑crossing enzyme platforms, and its broader vision of delivering meaningful quality‑of‑life improvements for people living with rare diseases.

Expanding into a Global Rare Disease Player through Deal-Driven Innovation

RARECast

The following RARECast podcast is made possible through support from the Global Genes Corporate Alliance. The members of the Corporate Alliance support Global Genes' mission and programs, work to meet the vital needs of people with rare diseases, and address inequities they face. To learn more about the Corporate Alliance or how your organization can become a member, join us at globalgenes.org and choose Corporate Alliance under the About tab.

I'm Daniel Levine and this is RARECast.

Chiesi Global Rare Diseases has rapidly evolved from a small regional rare disease business into a global organization, leveraging strategic deals and development bets to reshape standards of care for patients worldwide. Giacomo Chiesi, head of the unit, discusses how the business has grown through acquisitions, its move into CRISPR gene editing and blood-brain barrier-crossing enzyme platforms,

and its broader vision of delivering meaningful quality-of-life improvements for people living with rare diseases. Giacomo, thanks for joining us. Absolutely. Thanks for having me here today, Daniel. Really appreciate this opportunity. We first spoke on the RARECast when Chiesi Global Rare Diseases was in its early days. It's now been six years.

What is fundamentally different about the organization today? Well, a lot of things have changed. They're all positive. In the last six years, we've made a lot of great progress. For example, we've gone from initially, you know, we were, I think, between 50 and 100 people, and now we have about 800 people that are fully dedicated to rare diseases at the organization. So you can tell it's a demonstrable, important progress.

And then additionally, when we started off six years ago, we had an initial portfolio of different therapeutic alternatives for patients that span four or five different diseases, and we've expanded considerably.

Expanding into a Global Rare Disease Player through Deal-Driven Innovation

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Expanding into a Global Rare Disease Player through Deal-Driven Innovation

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.